AGIOS PHARMACEUTICALS, INC. Revenue from Related Parties
AGIOS PHARMACEUTICALS, INC. (AGIO) reported Revenue from Related Parties of $7.34 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-04.
Discontinued › Income Statement › Other Income
us-gaap:RevenueFromRelatedParties · last filed 2018-05-04
- AGIOS PHARMACEUTICALS, INC. revenue from related parties for the quarter ending 2018-03-31 was $7.34M, a 30.10% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. revenue from related parties for the quarter ending 2017-12-31 was $8.58M, a 62.13% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. revenue from related parties for the quarter ending 2017-09-30 was $10.64M, a 18.45% increase year-over-year.
- AGIOS PHARMACEUTICALS, INC. revenue from related parties for the quarter ending 2017-03-31 was $10.51M, a 66.41% decline year-over-year.
- AGIOS PHARMACEUTICALS, INC. revenue from related parties for fiscal 2017 was $41.07M, a 8.50% decline from fiscal 2016.
- AGIOS PHARMACEUTICALS, INC. revenue from related parties for fiscal 2016 was $44.89M, a 24.07% decline from fiscal 2015.
- AGIOS PHARMACEUTICALS, INC. revenue from related parties for fiscal 2015 was $59.12M, a 9.55% decline from fiscal 2014.
- AGIOS PHARMACEUTICALS, INC. revenue from related parties for fiscal 2014 was $65.36M, a 155.82% increase from fiscal 2013.
| Period end | Revenue from Related Parties 3 month | Revenue from Related Parties 6 month | Revenue from Related Parties 6 month as first filed | Revenue from Related Parties 9 month | Revenue from Related Parties 9 month as first filed | Revenue from Related Parties 12 month | Revenue from Related Parties 12 month as first filed |
|---|---|---|---|---|---|---|---|
| 2018-03-31 | $7.34M 10-Q · filed 2018-05-04 | $15.92M derived: sum of 2 quarters · filed 2018-05-04 | $26.57M derived: sum of 3 quarters · filed 2018-05-04 | ||||
| 2017-12-31 | $8.58M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | $19.22M derived: sum of 2 quarters · filed 2018-02-14 | $41.07M 10-K · filed 2018-02-14 | ||||
| 2017-09-30 | $10.64M 10-Q · filed 2017-11-01 | $32.50M 10-Q · filed 2017-11-01 | |||||
| 2017-03-31 | $10.51M 10-Q · filed 2018-05-04 | $33.16M derived: sum of 2 quarters · filed 2018-05-04 | $42.14M derived: sum of 3 quarters · filed 2018-05-04 | $49.12M derived: sum of 4 quarters · filed 2018-05-04 | |||
| 2016-12-31 | $22.65M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | $31.63M derived: sum of 2 quarters · filed 2018-02-14 | $38.61M derived: sum of 3 quarters · filed 2018-02-14 | $44.89M 10-K · filed 2018-02-14 | $69.89M 10-K · filed 2017-02-16 | ||
| 2016-09-30 | $8.98M 10-Q · filed 2017-11-01 | $15.96M derived: sum of 2 quarters · filed 2017-11-01 | $22.24M 10-Q · filed 2017-11-01 | $47.24M 10-Q · filed 2016-11-03 | $53.46M derived: sum of 4 quarters · filed 2018-02-14 | ||
| 2016-06-30 | $6.98M 10-Q · filed 2017-08-08 | $13.30M 10-Q · filed 2017-08-08 | $38.26M 10-Q · filed 2016-08-08 | $44.48M derived: sum of 3 quarters · filed 2018-02-14 | $49.96M derived: sum of 4 quarters · filed 2018-02-14 | ||
| 2016-03-31 | $31.28M 10-Q · filed 2017-05-04 | $37.50M derived: sum of 2 quarters · filed 2018-02-14 | $42.98M derived: sum of 3 quarters · filed 2018-02-14 | $56.20M derived: sum of 4 quarters · filed 2018-02-14 | |||
| 2015-12-31 | $6.22M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-14 | $11.70M derived: sum of 2 quarters · filed 2018-02-14 | $24.92M derived: sum of 3 quarters · filed 2018-02-14 | $59.12M 10-K · filed 2018-02-14 | |||
| 2015-09-30 | $5.48M 10-Q · filed 2016-11-03 | $18.70M derived: sum of 2 quarters · filed 2016-11-03 | $52.90M 10-Q · filed 2016-11-03 | $67.54M derived: sum of 4 quarters · filed 2017-02-16 | |||
| 2015-06-30 | $13.22M 10-Q · filed 2016-08-08 | $47.42M 10-Q · filed 2016-08-08 | $62.06M derived: sum of 3 quarters · filed 2017-02-16 | $95.96M derived: sum of 4 quarters · filed 2017-02-16 | |||
| 2015-03-31 | $34.20M 10-Q · filed 2016-05-09 | $48.84M derived: sum of 2 quarters · filed 2017-02-16 | $82.74M derived: sum of 3 quarters · filed 2017-02-16 | $91.15M derived: sum of 4 quarters · filed 2017-02-16 | |||
| 2014-12-31 | $14.64M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-16 | $48.54M derived: sum of 2 quarters · filed 2017-02-16 | $56.95M derived: sum of 3 quarters · filed 2017-02-16 | $65.36M 10-K · filed 2017-02-16 | |||
| 2014-09-30 | $33.90M 10-Q · filed 2015-11-06 | $42.31M derived: sum of 2 quarters · filed 2015-11-06 | $50.72M 10-Q · filed 2015-11-06 | $57.47M derived: sum of 4 quarters · filed 2016-02-26 | |||
| 2014-06-30 | $8.41M 10-Q · filed 2015-08-07 | $16.82M 10-Q · filed 2015-08-07 | $23.57M derived: sum of 3 quarters · filed 2016-02-26 | $29.83M derived: sum of 4 quarters · filed 2016-02-26 | |||
| 2014-03-31 | $8.41M 10-Q · filed 2015-05-11 | $15.15M derived: sum of 2 quarters · filed 2016-02-26 | $21.42M derived: sum of 3 quarters · filed 2016-02-26 | ||||
| 2013-12-31 | $6.74M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-26 | $13.01M derived: sum of 2 quarters · filed 2016-02-26 | $25.55M 10-K · filed 2016-02-26 | ||||
| 2013-09-30 | $6.27M 10-Q · filed 2014-11-07 | $18.80M 10-Q · filed 2014-11-07 | |||||
| 2012-12-31 | $25.07M 10-K · filed 2015-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |